⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL152386 | 0.81 | — | — | |
| SCHEMBL70682 | 0.81 | — | — | |
| SCHEMBL2921029 | 0.74 | — | — | |
| SCHEMBL3681941 | 0.74 | — | — | |
| SCHEMBL5643512 | 0.74 | — | — | |
| SCHEMBL31175983 | 0.74 | — | — | |
| SCHEMBL31555006 | 0.74 | — | — | |
| SCHEMBL14225088 | 0.71 | PDE4D (0.37) | — | |
| SCHEMBL17366546 | 0.70 | — | — | |
| SCHEMBL21737224 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188073-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORP (US) | 2025-06-12 | — | — | US | disclosed |
| EP-4548918-A2 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | Incyte Corporation (US) | 2025-05-07 | — | — | EP | disclosed |
| CN-111989321-B | KRAS G12C inhibitors | 米拉蒂治疗股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| US-20240101553-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2024-03-28 | — | — | US | disclosed |
| US-20230373999-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-11-23 | — | — | US | disclosed |
| EP-3710439-B1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-02-15 | — | — | EP | disclosed |
| EP-4087843-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | Incyte Corporation (US) | 2022-11-16 | — | — | EP | disclosed |
| CN-114616232-A | Azepadinopyrimidine derivatives and medical application thereof | 正大天晴药业集团南京顺欣制药有限公司 | 2022-06-10 | — | — | CN | disclosed |
| WO-2021043322-A1 | AZEPINO PYRIMIDINE DERIVATIVES AND MEDICAL USE THEREOF | 正大天晴药业集团南京顺欣制药有限公司 | 2021-03-11 | — | — | WO | disclosed |
| CN-111989321-A | KRAS G12C inhibitors | 米拉蒂治疗股份有限公司 | 2020-11-24 | — | — | CN | disclosed |
| US-RE45173-E1 | Inhibitors of CYP 17 | NOVARTIS AG (CH) | 2014-09-30 | — | — | US | disclosed |
| US-20140228394-A1 | INHIBITORS OF CYP 17 | NOVARTIS AG (CH) | 2014-08-14 | — | — | US | disclosed |
| EP-2445903-B1 | 1,3-DISUBSTITUTED IMIDAZOLIDIN-2-ONE DERIVATIVES AS INHIBITORS OF CYP 17 | NOVARTIS AG (CH) | 2014-03-26 | — | — | EP | disclosed |
| US-20140045819-A1 | ALDOSTERONE SYNTHASE INHIBITORS | ELEXOPHARM GMBH (DE) | 2014-02-13 | — | — | US | disclosed |
| US-20140045819-A1 | ALDOSTERONE SYNTHASE INHIBITORS | ELEXOPHARM GMBH (DE) | 2014-02-13 | — | — | US | disclosed |
| US-20140045819-A1 | ALDOSTERONE SYNTHASE INHIBITORS | ELEXOPHARM GMBH (DE) | 2014-02-13 | — | — | US | disclosed |
| CN-102803250-A | 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of CYP17 | NOVARTIS AG | 2012-11-28 | — | — | CN | disclosed |
| US-8263635-B2 | Inhibitors of CYP 17 | NOVARTIS AG (CH) | 2012-09-11 | — | — | US | disclosed |
| WO-2012084678-A1 | NOVEL IMIDAZOLES USEFUL AS PLANT FUNGICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2012-06-28 | — | — | WO | disclosed |
| US-20100331326-A1 | Inhibitors of CYP 17 | NOVARTIS AG | 2010-12-30 | — | — | US | disclosed |